Yondelis

Chemical Nametrabectedin
Dosage FormInjection (intravenous; 1 mg/vial)
Drug ClassAlkylating agents
SystemSkin, Musculoskeletal
CompanyJanssen Biotech
Approval Year2015

Indication

  • For the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.
Last updated on 10/15/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Yondelis (trabectedin) Prescribing Information2015Janssen Products, LP, Horsham, PA